Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-29 07:35:22 - browse：74

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Why Talkspace is targeting Medicare, a tricky market

hotspot

entertainment

WSS

IVF doctors demand details after CooperSurgical lawsuit

Biden's 'march

For AI in health care standards, federal regulators join with industry group

The battle over 'scope creep' and who gets to be called 'doctor'

Florida health officials providing scant details on measles cases

Medicare drug price negotiation continues, as pharma counteroffers

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

In Memoriam: Notable people who died in 2023

State of the Union pitch: Bigger Medicare drug price negotiations

Bright Health sells Medicare Advantage business to Molina

Florida health officials providing scant details on measles cases

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Fetal cell organoids grown from amniotic fluid, study finds

In Memoriam: Notable people who died in 2023

A new crop of companies is reshaping the health data economy

Cancer drug shortages should be causing more outrage

Biden warns of ‘dark winter’ during final presidental debate

hotspot

Why patients can’t get everything they want on drug pricing

Stem cell biologist probes earliest stages of human development

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Senate panel puts off hardest PBM reforms for another day

Families look for replacement for GSK asthma drug Flovent

Will the FTC rein in IQVIA's health data empire?

knowledge

hotspot

entertainment

hotspot